Helen M. Thackray Biocryst Pharmaceuticals Inc (BCRX) insider trading activity

Helen M. Thackray is Chief R&D Officer of BIOCRYST PHARMACEUTICALS INC. Currently has a direct ownership of 384,843 shares of BCRX, which is worth approximately $2.95 Million. The most recent transaction as insider was on Dec 19, 2024, when has been sold 6,096 shares (Common Stock) at a price of $7.39 per share, resulting in proceeds of $45,049. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 385K

41.41% 3M change

54.14% 12M change

Total Value Held $2.95 Million

Helen M. Thackray Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Dec 19 2024	SELL Payment of exercise price or tax liability	$45,049 $7.39 p/Share	6,096 Reduced 1.56%	384,843 Common Stock
Dec 19 2024	BUY Grant, award, or other acquisition	-	125,950 Added 24.37%	390,939 Common Stock
Dec 14 2024	SELL Payment of exercise price or tax liability	$53,839 $7.53 p/Share	7,150 Reduced 2.63%	264,989 Common Stock
May 14 2024	BUY Open market or private purchase	$175,800 $5.86 p/Share	30,000 Added 9.93%	272,139 Common Stock
Mar 31 2024	SELL Payment of exercise price or tax liability	$38,227 $5.08 p/Share	7,525 Reduced 3.01%	242,139 Common Stock
Dec 19 2023	SELL Payment of exercise price or tax liability	$33,759 $6.05 p/Share	5,580 Reduced 2.19%	249,664 Common Stock
Dec 14 2023	SELL Payment of exercise price or tax liability	$19,489 $6.43 p/Share	3,031 Reduced 1.17%	255,244 Common Stock
Dec 14 2023	BUY Grant, award, or other acquisition	-	51,000 Added 16.49%	258,275 Common Stock
Apr 03 2023	SELL Open market or private sale	$58,029 $8.29 p/Share	7,000 Reduced 3.27%	207,275 Common Stock
Dec 19 2022	BUY Grant, award, or other acquisition	-	81,000 Added 27.43%	214,275 Common Stock
Dec 15 2022	SELL Open market or private sale	$34,031 $10.89 p/Share	3,125 Reduced 2.29%	133,275 Common Stock
Apr 01 2022	SELL Open market or private sale	$123,120 $16.2 p/Share	7,600 Reduced 5.28%	136,400 Common Stock
Dec 14 2021	BUY Grant, award, or other acquisition	-	44,000 Added 23.4%	144,000 Common Stock
Mar 31 2021	BUY Grant, award, or other acquisition	-	100,000 Added 50.0%	100,000 Common Stock

Also insider at

GLYC

GLYCOMIMETICS INC Healthcare

SVP Clinical Development, CMO

IMGN

ImmunoGen, Inc. Healthcare

Director

HMT

Helen M. Thackray

Chief R&D Officer

Durham, NC

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells BCRX shares.

Notify only if

Value

Insider Trading

Get notified when an Biocryst Pharmaceuticals Inc insider buys or sells BCRX shares.

Notify only if

Operation

Value

Type

News

Receive news related to BIOCRYST PHARMACEUTICALS INC

Track Activities on BCRX

Account